The Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting
October 26-28, 2012
Bethesda North Marriott Hotel & Convention Center
North Bethesda, MD
Program Organizers
Cornelis J.M. Melief, MD, PhD - Leinden University Medical Center
Antoni Ribas, MD - University of California, Los Angeles Medical Center
David F. Stroncek, MD - National Institutes of Health
Program Summary
The SITC 27th Annual Meeting program format and content was designed to address identified needs/practice gaps and promote:
- Exchange between basic and clinical researchers, thus improving the caliber of the science and promoting translation
- Discussion on potential hurdles in cancer immunotherapy from the trial design and regulatory perspective
- Integrated understanding of the state of cancer immunotherapy research in today’s environment, identification of potential funding opportunities, and mentoring of junior investigators
- Discussion of novel therapies and applications based on the research presented
- Interactions with industry to promote access to novel agents for clinical development
Target AudienceThe audience for the SITC 27th Annual Meeting was basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, postdoctoral fellows, and allied health professionals involved in cancer research.
Presentations and video recordings are available based on permission from presenters.
#ClinicalTrials #Biomarkers #BreastCancers #ColorectalCancer #PresentationSlides #AnnualMeeting #CombinationTherapy #ImmuneCheckpointInhibitors #TherapeuticAntibodies #Vaccines #AlliedHealth #Clinician #Industry #Oncologist #Researcher #2012 #BrainCancers #CervicalCancer #GenitourinaryCancers #Lymphoma#Melanoma #Myeloma #OvarianCancer #AdoptiveCellTherapy #Cytokines